Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D019313:BRCA1 Protein / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D008870:Microtubules / Q000187:drug effects*; D048055:Mitogen-Activated Protein Kinase 8; D048056:Mitogen-Activated Protein Kinase 9; D020929:Mitogen-Activated Protein Kinase Kinases / Q000096:biosynthesis / Q000235:genetics; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000502:physiology; D017239:Paclitaxel / Q000494:pharmacology; D016755:Proto-Oncogene Proteins c-jun / Q000235:genetics / Q000378:metabolism; D016337:RNA, Catalytic / Q000494:pharmacology*; D012333:RNA, Messenger / Q000187:drug effects; D008941:Spindle Apparatus / Q000187:drug effects; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000494:pharmacology